<DOC>
	<DOCNO>NCT02585388</DOCNO>
	<brief_summary>The CHEOPS study aim confirm clinical benefit combination anti-aromatase metronomic chemotherapy treatment</brief_summary>
	<brief_title>Addition Aromatase Navelbine Pretreated Metastatic Breast Cancer .</brief_title>
	<detailed_description>The CHEOPS study aim confirm clinical benefit combination anti-aromatase metronomic chemotherapy treatment would theoretical advantage well tolerated effective chemotherapy alone even anti-aromatase therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Age ≥ 50 year . 2 . Histologically proven breast cancer . 3 . Progesterone /or oestrogene receptor positive . 4 . HER2 negative primary tumour . 5 . Patient take hormonotherapy , progression , already treat least one line antiaromatase nonsteroidal hormonotherapy least line chemotherapy . 6 . Patient begin second third line chemotherapy . 7 . Presence one several measurable ( ) assessable ( ) metastatic lesion ( ) .In case isolate bone lesion ( ) : need nonirradiated osteolytic component consider lesion ( ) target ( ) elevation CA153 . 8 . Post menopausal woman . 9 . ECOG 0 , 1 2 . 10 . Adequate biological function . Neutrophil ≥ 1,5.E9/L Platelets ≥ 100.E9/L Creatinine clearance ≥ 30 mL/min Total bilirubin ≤ 1,5 x upper limit normal ( ULN ) Alkaline phosphatase ≤ 2,5 x ULN ALT , AST ≤ 1,5 x ULN absence liver metastases ≤ 3 x ULN liver metastasis . 11 . Patient life expectancy great 3 month . 12 . Signed informed consent enrollment . 13. affiliation social security scheme 1 . Patient locate single metastatic tumoral relapse , accessible surgical treatment . 2 . Patient already receive 2 line chemotherapy metastatic advanced decease 3 . Patient already receive treatment Navelbine® 4 . Patient require immediate locate radiotherapy analgesic action 5 . Patient nonirradiated cerebral symptomatic metastasis , symptomatic pulmonary carcinomatosis lymphangitis 6 . Simultaneous administration another chemotherapy hormonotherapy antitumoral drug 7 . Patient already receive another treatment ongoing evaluation within 30 day screen visit 8 . Known positive serology HIV 9 . Previous cancer within 5 year entry study , except situ carcinoma cervix spino basal cell carcinoma skin nonmelanoma skin cancer adequate treatment . 10 . Any serious concomitant pathology / uncontrolled could compromise participation study ( include uncontrolled diabetes , uncontrolled hypertension , severe infection , profound malnutrition , unstable angina congestive heart failure class III IV accord New York Heart Association ventricular arrhythmia , progressive coronary artery disease , myocardial infarction within last six month , chronic liver kidney disease , progressive ulceration digestive tract , CNS disorder ) . 11 . Disorder gastrointestinal function ( GI ) pathology likely significantly interfere absorption Navelbine , Letrozole Anastrozole ( eg . Ulcerative disease , uncontrolled nausea , vomit , diarrhea , syndrome malabsorption , resection small intestine ) . 12 . Known hypersensitivity letrozole , anastrozole , vinorelbine vincoalkaloids component . 13 . Patient fructose intolerance , galactose , Lapp lactase deficiency malabsorption glucose galactose ( rare hereditary disease ) . 14 . Patient history poor compliance medical treatment . 15 . Patient monitor regularly family reason , geographical , social psychological . 16 . Patient alter mental status would allow understand study give inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pretreated metastatic breast cancer</keyword>
</DOC>